U.S. Luxury Stock News

Taysha Gene Therapies reported full-year 2025 results on March 19, 2026, posting US$9.77 million in sales versus US$8.33 million a year earlier, alongside a net loss of US$109 million and appointing Brad Martin as Senior Vice President, Market Access and Value in February 2026. At the same time, the company highlighted clinical and regulatory progress for its Rett syndrome program TSHA-102, including FDA Breakthrough Therapy designation, written FDA alignment on pivotal trial design and...

Live Oak Bancshares overview Live Oak Bancshares (LOB) has drawn investor attention after recent price moves, with the stock showing a 22.1% decline over the past month and a 12.1% decline over the past 3 months, despite a 16.9% total return over the past year. See our latest analysis for Live Oak Bancshares. The recent 22.1% 1 month share price decline and 12.1% 3 month share price decline contrast with the 16.9% 1 year total shareholder return, suggesting near term momentum has cooled while...

Recent performance context First Industrial Realty Trust (FR) has seen its share price move lower recently, with a 3.1% decline in the past day, a 5.2% decline over the past week, and an 8.2% decline over the past month. See our latest analysis for First Industrial Realty Trust. Despite the recent weak momentum in the share price, with short term share price returns in negative territory, First Industrial Realty Trust still shows a positive 1 year total shareholder return of 10.2% and a 5...

On March 11, 2026, Barclays analyst Tom O'Malley initiated coverage of Nova Ltd. with an “Overweight” rating, citing its exposure to metrology demand as semiconductor manufacturing becomes more measurement intensive. This fresh endorsement underscores how Nova’s broadened metrology portfolio and recent tool qualifications could reinforce its role in the evolving wafer fab equipment ecosystem. We’ll now examine how Barclays’ positive initiation, focused on Nova’s metrology positioning, may...

Sensata Technologies Holding (ST) has drawn investor attention after recent share price weakness, with the stock showing declines over the past week, month, and past 3 months that contrast with its positive 1 year total return. See our latest analysis for Sensata Technologies Holding. The recent 13.5% decline in the 1 month share price contrasts with a 24.1% 1 year total shareholder return. This suggests that earlier optimism has cooled and momentum has faded in the short term, as investors...

XPeng Inc. has already reported fourth-quarter 2025 results, with revenue rising to CNY 22,253.76 million and net income of CNY 383.21 million, marking its first-ever quarterly profit and sharply narrowing full-year losses compared with 2024. Despite this profitability milestone and strong 2025 delivery growth, management’s guidance for a double-digit revenue and delivery decline in the first quarter of 2026 highlights ongoing pressure from subsidy rollbacks and intense EV competition. Now...

Earlier in March 2026, Freshpet was instructed by the National Advertising Division to stop implying its dog food is “human grade” after a challenge from rival The Farmer’s Dog, and the company has said it will comply. This ruling highlights how marketing language around ingredient quality and product positioning can become a competitive battleground in the premium fresh pet food category. Next, we’ll examine how Freshpet’s decision to stop “human grade” claims could influence its branding,...

Berkshire Hathaway has significantly expanded its stake in Chevron, signaling increased institutional interest in NYSE:CVX. The move comes during a period of oil market volatility and heightened energy sector price swings. Chevron shares most recently closed at $201.73. For investors watching NYSE:CVX, Berkshire Hathaway's larger position highlights Chevron's role as a major integrated energy company with meaningful scale and liquidity. The stock has returned 29.4% year to date and 28.0%...

Why Savara Stock Is Back on Investors’ Radar Savara (SVRA) shares have been under pressure recently, with negative returns over the past week, month and past 3 months. This has prompted investors to reassess this clinical stage rare respiratory disease specialist. See our latest analysis for Savara. While the recent 1 day share price return of 3.88% decline and 90 day share price return of 23.34% decline suggest fading short term momentum, the 1 year total shareholder return of 75.89%...

CenterPoint Energy (CNP) is back on investor watch after recent trading showed mixed short term returns, including a 2.8% one day decline alongside a gain over the past 3 months. See our latest analysis for CenterPoint Energy. The latest moves sit within a stronger upward trend, with an 11.16% 90 day share price return and a 20.19% one year total shareholder return suggesting momentum has been building despite recent softness around the US$42.02 level. If you are comparing CenterPoint Energy...

Earlier in March 2026, Joby Aviation completed piloted electric air taxi demonstration flights around San Francisco Bay, began testing its first FAA-conforming aircraft for Type Inspection Authorization, and was selected to participate in the White House-backed eVTOL Integration Pilot Program across 10 U.S. states. These steps give Joby a path to start early operations in multiple regions while regulators evaluate its aircraft for eventual commercial service, tightening the link between its...

In March 2026, Rapport Therapeutics announced it had granted Tenacia Biotechnology exclusive rights to develop and commercialize its investigational drug RAP-219 in Greater China, in exchange for a US$20,000,000 upfront payment, up to about US$308,000,000 in potential milestones and other payments, and tiered royalties on future regional sales. Beyond the financial terms, the agreement positions Tenacia to lead Phase 3 trial sites in China for RAP-219 in focal onset seizures, potentially...

What H.B. Fuller’s Recent Share Performance Tells Investors H.B. Fuller (FUL) has drawn attention after a recent share price slide, with the stock down about 25% over the past month and roughly 18% over the past 3 months, prompting closer scrutiny from investors. See our latest analysis for H.B. Fuller. Looking beyond the recent slump, H.B. Fuller’s 30 day share price return of 25.25% and year to date share price return of 18.31% both suggest fading momentum. Meanwhile, the 1 year total...

Otis Worldwide (OTIS) is putting accessible mobility at the center of its product story, unveiling its Viva elevator solutions aimed at safer, more intuitive rides for aging populations and broader tenant needs worldwide. See our latest analysis for Otis Worldwide. Despite the Viva launch and the upcoming appearance at the JPMorgan Industrials Conference, recent trading has been soft, with a 30 day share price return decline of 14.17% and a 1 year total shareholder return decline of 19.96%,...

Hewlett Packard Enterprise (HPE) just rolled out a cluster of AI focused launches and NVIDIA backed partnerships, spanning AI factories, sovereign systems and edge grids, that collectively sharpen its role as an infrastructure supplier. See our latest analysis for Hewlett Packard Enterprise. Despite the flurry of AI factory and sovereign AI announcements, HPE’s 1 day share price return of 1.94% and 90 day share price return of 12.19% suggest momentum has cooled recently, even as 1 year and...

United Airlines Holdings (UAL) drew fresh investor attention after CEO Scott Kirby warned that sharply higher jet fuel prices tied to Iran tensions are pressuring costs, prompting a 5% cut to near term flight capacity. See our latest analysis for United Airlines Holdings. The recent warning on fuel costs and capacity cuts comes after a weak run in the share price, with a 30 day share price return of 20.42% and a 90 day share price return of 22.47%, even though the 1 year total shareholder...

ZTO Express (Cayman) Inc. has already reported its fourth-quarter and full-year 2025 results, showing higher sales and net income year on year, and also announced a semi-annual US$0.38 per-share dividend, completion of a US$2.00 billion buyback, and approval of a new US$1.50 billion repurchase plan. Together, the stronger earnings, larger cash returns to shareholders, and confirmation that repurchases will be funded from existing cash highlight management’s confidence in the business and its...

What Jones Lang LaSalle (JLL) offers investors today Jones Lang LaSalle (JLL) sits at the center of global commercial real estate, with a market value of about US$13.8b and a broad mix of fee based services, investment management and technology solutions. See our latest analysis for Jones Lang LaSalle. The recent 1 month share price return of 6.43% and 90 day decline of 13.71% suggest momentum has cooled in the short term. However, the 1 year total shareholder return of 17.40% and 3 year...

In March 2026, Choice Hotels International’s Ascend Hotel Collection passed the 500-property mark, adding new U.S. locations such as The Harrison Hotel in Downtown Hollywood, Florida and The Gould Hotel in Seneca Falls, New York. This expansion is underpinned by a 70-hotel pipeline and fresh international moves into Poland, Chile, Kenya’s Maasai Mara, and a master franchise deal in China adding over 9,500 rooms to the brand. We’ll now examine how Ascend’s 500-property scale and China master...

Zimmer Biomet Holdings (ZBH) drew fresh attention after reporting 10.9% year-on-year revenue growth that came in 0.9% above analyst expectations, while slightly missing full-year EPS guidance despite progress on EPS, free cash flow, and acquisitions. See our latest analysis for Zimmer Biomet Holdings. The latest earnings update landed against a weak share price backdrop, with a 30 day share price return showing an 11% decline and a 1 year total shareholder return showing a 19.86% decline...

Event context and recent price performance PTC (PTC) shares recently closed at US$149.81, with the stock showing a 0.6% decline over the past day and a 3.9% decline over the past week. This sets the backdrop for investors assessing current levels. See our latest analysis for PTC. While the recent share price return has been weak, with a 16.3% decline over 90 days and an 11.9% decline year to date, the 3 year total shareholder return of 23.1% and 5 year total shareholder return of 10.6% show a...

Protagonist Therapeutics recently held a special call to discuss the U.S. FDA approval of ICOTYDE (icotrokinra) for the treatment of moderate to severe plaque psoriasis, marking a major regulatory milestone for the company. This approval highlights the company’s ability to successfully advance a novel therapeutic into the market for a serious, chronic skin condition with significant unmet patient needs. We’ll now explore how the FDA approval of ICOTYDE for moderate to severe plaque psoriasis...

Four Corners Property Trust (FCPT) is back on investor radars after recent share price moves, with the stock last closing at US$24.26 and showing mixed returns over the past year and past 3 months. See our latest analysis for Four Corners Property Trust. Recent trading has been softer, with a 1-day share price return of 4.0% decline and a 7-day share price return of 5.4% decline, while the 1-year total shareholder return of 8.7% decline contrasts with positive 3 and 5 year total shareholder...

Visteon (VC) is back in focus after announcing an edge-to-cloud AI arbitration platform for software-defined vehicles built with NVIDIA technology, tying real-time in-car processing more tightly to cloud-based AI. See our latest analysis for Visteon. The NVIDIA partnership comes at a time when Visteon’s 1-year total shareholder return of 7.18% contrasts with a weaker 3-year total shareholder return, which shows a 44.07% decline. Recent 30 to 90 day share price returns also suggest that...